Please enable JavaScript to continue using this application.

Compare $CLDX vs $SLS | Chartloom

Compare

$CLDX vs $SLS

Celldex Therapeutics Inc · Sellas Life Sciences Group Inc

CLDX

Celldex Therapeutics Inc

SLS

Sellas Life Sciences Group Inc

Compare $CLDX vs $SLS

Comparing Celldex Therapeutics Inc and Sellas Life Sciences Group Inc

CLDXCelldex Therapeutics Inc

SLSSellas Life Sciences Group Inc

CLDXCelldex Therapeutics Inc

Market cap

$2.35B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

1,016.81x

Rev growth (TTM)

-97.3%

YTD performance

10.7%

52W performance

9.7%

FCF yield

-10.3%

SLSSellas Life Sciences Group Inc

Market cap

$2.29B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

167.8%

52W performance

503.6%

FCF yield

-1.2%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

CLDX

SLS

Detailed metrics comparison

CLDX

Celldex Therapeutics Inc

SLS

Sellas Life Sciences Group Inc

Market Cap

CLDX$2.35B

SLS$2.29B

Enterprise Value

CLDX$2.30B

SLS$2.15B

Price

CLDX$29.89

SLS$11.65

P/E Ratio

CLDXN/A

SLSN/A

P/S Ratio

CLDX14,848.52x

SLS817.53x

EV/Sales

CLDX14,548.18x

SLS769.83x

EV/EBITDA

CLDX0.00x

SLS0.00x

P/B Ratio

CLDX3.48x

SLS17.22x

P/FCF Ratio

CLDXN/A

SLSN/A

EV/FCF

CLDX-9.49x

SLS-75.73x

PEG Ratio

CLDXN/A

SLSN/A

Forward P/E (NTM)

CLDXN/A

SLSN/A

Forward P/S (NTM)

CLDX1,016.81x

SLSN/A

Revenue (TTM)

CLDX$158K

SLS$0

Revenue Growth (YoY)

CLDX-97.3%

SLSN/A

Forward Rev Growth

CLDX637.2%

SLS144.9%

Gross Margin (TTM)

CLDX17.6%

SLS93.1%

Operating Margin (TTM)

CLDX0.0%

SLS0.0%

EBITDA Margin (TTM)

CLDX-204070.9%

SLS0.0%

Net Margin (TTM)

CLDX-190220.9%

SLS0.0%

FCF Margin (TTM)

CLDX-153231.0%

SLSN/A

Net Income (TTM)

CLDX$-301M

SLS$-32M

FCF (TTM)

CLDX$-242M

SLS$-28M

EPS (TTM)

CLDX-$3.86

SLS-$0.17

ROE (TTM)

CLDX-5235.0%

SLS-3591.0%

ROA (TTM)

CLDX-4761.0%

SLS-3334.0%

ROIC (TTM)

CLDX-5235.0%

SLS-3591.0%

Cash

CLDX$47M

SLS$138M

Debt

CLDX$0

SLS$0

Net Cash/Debt

CLDX$47M

SLS$138M

Current Ratio (TTM)

CLDX11.82x

SLS18.83x

Quick Ratio (TTM)

CLDX11.71x

SLS18.29x

Debt/Equity (TTM)

CLDX0.00x

SLS0.00x

Debt/Assets (TTM)

CLDX0.0%

SLS0.0%

Interest Coverage (TTM)

CLDXN/A

SLSN/A

Net Debt/EBITDA (TTM)

CLDX0.00x

SLS0.00x

Beta

CLDX0.99

SLS2.68

52W Performance

CLDX9.7%

SLS503.6%

YTD Performance

CLDX10.7%

SLS167.8%

% from 52W High

CLDX-33.8%

SLS-26.6%

% from 52W Low

CLDX35.2%

SLS738.1%

Asset Turnover (TTM)

CLDX0.00x

SLS0.09x

FCF Yield (TTM)

CLDX-10.3%

SLS-1.2%

Earnings Yield (TTM)

CLDX-12.8%

SLS-1.4%

Dividend Yield (TTM)

CLDXN/A

SLSN/A

Rule of 40

CLDX-153,328.3

SLS0.0

EV/GP/RG

CLDX42.93

SLSN/A

Ticker research

View CLDX research View SLS research

Metric	CLDX Celldex Therapeutics Inc	SLS Sellas Life Sciences Group Inc
Market & Valuation
Market Cap	$2.35B	$2.29B
Enterprise Value	$2.30B	$2.15B
Price	$29.89	$11.65
P/E Ratio	N/A	N/A
P/S Ratio	14,848.52x	817.53x
EV/Sales	14,548.18x	769.83x
EV/EBITDA	0.00x	0.00x
P/B Ratio	3.48x	17.22x
P/FCF Ratio	N/A	N/A
EV/FCF	-9.49x	-75.73x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	1,016.81x	N/A
Revenue & Growth
Revenue (TTM)	$158K	$0
Revenue Growth (YoY)	-97.3%	N/A
Forward Rev Growth	637.2%	144.9%
Profitability
Gross Margin (TTM)	17.6%	93.1%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-204070.9%	0.0%
Net Margin (TTM)	-190220.9%	0.0%
FCF Margin (TTM)	-153231.0%	N/A
Net Income (TTM)	$-301M	$-32M
FCF (TTM)	$-242M	$-28M
EPS (TTM)	-$3.86	-$0.17
ROE (TTM)	-5235.0%	-3591.0%
ROA (TTM)	-4761.0%	-3334.0%
ROIC (TTM)	-5235.0%	-3591.0%
Financial Health
Cash	$47M	$138M
Debt	$0	$0
Net Cash/Debt	$47M	$138M
Current Ratio (TTM)	11.82x	18.83x
Quick Ratio (TTM)	11.71x	18.29x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.99	2.68
52W Performance	9.7%	503.6%
YTD Performance	10.7%	167.8%
% from 52W High	-33.8%	-26.6%
% from 52W Low	35.2%	738.1%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.09x
FCF Yield (TTM)	-10.3%	-1.2%
Earnings Yield (TTM)	-12.8%	-1.4%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-153,328.3	0.0
EV/GP/RG	42.93	N/A
Ticker research	View CLDX research	View SLS research

Valuation

P/S Ratio

SLS

817.53x

CLDX

14,848.52x

EV/FCF

SLS

-75.73x

CLDX

-9.49x

Growth & revenue

Revenue Growth TTM

CLDX

-97.3%

Forward Revenue Growth

CLDX

637.2%

SLS

144.9%

Profitability & performance

Gross Margin

SLS

93.1%

CLDX

17.6%

ROE

SLS

-3591.0%

CLDX

-5235.0%

FCF Yield %

SLS

-1.2%

CLDX

-10.3%

52-Week Performance

SLS

503.6%

CLDX

9.7%

Detailed metrics comparison

CLDX

Celldex Therapeutics Inc

SLS

Sellas Life Sciences Group Inc

Market Cap

CLDX$2.35B

SLS$2.29B

Enterprise Value

CLDX$2.30B

SLS$2.15B

Price

CLDX$29.89

SLS$11.65

P/E Ratio

CLDXN/A

SLSN/A

P/S Ratio

CLDX14,848.52x

SLS817.53x

EV/Sales

CLDX14,548.18x

SLS769.83x

EV/EBITDA

CLDX0.00x

SLS0.00x

P/B Ratio

CLDX3.48x

SLS17.22x

P/FCF Ratio

CLDXN/A

SLSN/A

EV/FCF

CLDX-9.49x

SLS-75.73x

PEG Ratio

CLDXN/A

SLSN/A

Forward P/E (NTM)

CLDXN/A

SLSN/A

Forward P/S (NTM)

CLDX1,016.81x

SLSN/A

Revenue (TTM)

CLDX$158K

SLS$0

Revenue Growth (YoY)

CLDX-97.3%

SLSN/A

Forward Rev Growth

CLDX637.2%

SLS144.9%

Gross Margin (TTM)

CLDX17.6%

SLS93.1%

Operating Margin (TTM)

CLDX0.0%

SLS0.0%

EBITDA Margin (TTM)

CLDX-204070.9%

SLS0.0%

Net Margin (TTM)

CLDX-190220.9%

SLS0.0%

FCF Margin (TTM)

CLDX-153231.0%

SLSN/A

Net Income (TTM)

CLDX$-301M

SLS$-32M

FCF (TTM)

CLDX$-242M

SLS$-28M

EPS (TTM)

CLDX-$3.86

SLS-$0.17

ROE (TTM)

CLDX-5235.0%

SLS-3591.0%

ROA (TTM)

CLDX-4761.0%

SLS-3334.0%

ROIC (TTM)

CLDX-5235.0%

SLS-3591.0%

Cash

CLDX$47M

SLS$138M

Debt

CLDX$0

SLS$0

Net Cash/Debt

CLDX$47M

SLS$138M

Current Ratio (TTM)

CLDX11.82x

SLS18.83x

Quick Ratio (TTM)

CLDX11.71x

SLS18.29x

Debt/Equity (TTM)

CLDX0.00x

SLS0.00x

Debt/Assets (TTM)

CLDX0.0%

SLS0.0%

Interest Coverage (TTM)

CLDXN/A

SLSN/A

Net Debt/EBITDA (TTM)

CLDX0.00x

SLS0.00x

Beta

CLDX0.99

SLS2.68

52W Performance

CLDX9.7%

SLS503.6%

YTD Performance

CLDX10.7%

SLS167.8%

% from 52W High

CLDX-33.8%

SLS-26.6%

% from 52W Low

CLDX35.2%

SLS738.1%

Asset Turnover (TTM)

CLDX0.00x

SLS0.09x

FCF Yield (TTM)

CLDX-10.3%

SLS-1.2%

Earnings Yield (TTM)

CLDX-12.8%

SLS-1.4%

Dividend Yield (TTM)

CLDXN/A

SLSN/A

Rule of 40

CLDX-153,328.3

SLS0.0

EV/GP/RG

CLDX42.93

SLSN/A

Ticker research

View CLDX research View SLS research

Metric	CLDX Celldex Therapeutics Inc	SLS Sellas Life Sciences Group Inc
Market & Valuation
Market Cap	$2.35B	$2.29B
Enterprise Value	$2.30B	$2.15B
Price	$29.89	$11.65
P/E Ratio	N/A	N/A
P/S Ratio	14,848.52x	817.53x
EV/Sales	14,548.18x	769.83x
EV/EBITDA	0.00x	0.00x
P/B Ratio	3.48x	17.22x
P/FCF Ratio	N/A	N/A
EV/FCF	-9.49x	-75.73x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	1,016.81x	N/A
Revenue & Growth
Revenue (TTM)	$158K	$0
Revenue Growth (YoY)	-97.3%	N/A
Forward Rev Growth	637.2%	144.9%
Profitability
Gross Margin (TTM)	17.6%	93.1%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-204070.9%	0.0%
Net Margin (TTM)	-190220.9%	0.0%
FCF Margin (TTM)	-153231.0%	N/A
Net Income (TTM)	$-301M	$-32M
FCF (TTM)	$-242M	$-28M
EPS (TTM)	-$3.86	-$0.17
ROE (TTM)	-5235.0%	-3591.0%
ROA (TTM)	-4761.0%	-3334.0%
ROIC (TTM)	-5235.0%	-3591.0%
Financial Health
Cash	$47M	$138M
Debt	$0	$0
Net Cash/Debt	$47M	$138M
Current Ratio (TTM)	11.82x	18.83x
Quick Ratio (TTM)	11.71x	18.29x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.99	2.68
52W Performance	9.7%	503.6%
YTD Performance	10.7%	167.8%
% from 52W High	-33.8%	-26.6%
% from 52W Low	35.2%	738.1%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.09x
FCF Yield (TTM)	-10.3%	-1.2%
Earnings Yield (TTM)	-12.8%	-1.4%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-153,328.3	0.0
EV/GP/RG	42.93	N/A
Ticker research	View CLDX research	View SLS research